Z Kevin Lu
Biographic Data
| ID | 9800718 |
|---|---|
| NAME | Z Kevin Lu |
| GIVEN NAMES | Z Kevin |
| FAMILY NAME | Lu |
| SIGNATURE | LU Z K |
| AFFILIATIONS | University of South Carolina |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Lifetime cost-effectiveness of lecanemab for early Alzheimer’s disease
Introduction: monoclonal antibody to receive FDA approval for the treatment of early Alzheimer's disease (AD), following aducanumab. Unlike aducanumab, which faced restricted Medicare coverage, lecanemab received traditional approval in 2023, resulting in broader access through Medicare. Despite these developments, the comparative cost-effectiveness of lecanemab and aducanumab has not been fully established. This study aimed to assess whether lec…
Lowering drug prices and enhancing pharmaceutical affordability
To cope with the increasing healthcare costs brought about by the universal health insurance programme, national volume-based procurement (NVBP) was implemented in China to reduce drug prices. However, the impact of NVBP remains unknown. We reported the effects of the NVBP pilot programme on medication affordability and discussed the challenges and recommendations for further reforms. A total of 25 molecules won the bidding in the NVBP pilot prog…
No prominent works on this page.
Lowering drug prices and enhancing pharmaceutical affordability
To cope with the increasing healthcare costs brought about by the universal health insurance programme, national volume-based procurement (NVBP) was implemented in China to reduce drug prices. However, the impact of NVBP remains unknown. We reported the effects of the NVBP pilot programme on medication affordability and discussed the challenges and recommendations for further reforms. A total of 25 molecules won the bidding in the NVBP pilot prog…
Lifetime cost-effectiveness of lecanemab for early Alzheimer’s disease
Introduction: monoclonal antibody to receive FDA approval for the treatment of early Alzheimer's disease (AD), following aducanumab. Unlike aducanumab, which faced restricted Medicare coverage, lecanemab received traditional approval in 2023, resulting in broader access through Medicare. Despite these developments, the comparative cost-effectiveness of lecanemab and aducanumab has not been fully established. This study aimed to assess whether lec…
Alzheimer's disease research and treatments (1 works) · Business (1 works) · China (1 works) · Cholinesterase and Neurodegenerative Diseases (1 works) · Dementia and Cognitive Impairment Research (1 works) · Disease (1 works) · Drug (1 works) · Drug prices (1 works) · Economics (1 works) · Health Systems, Economic Evaluations, Quality of Life (1 works)